$INTS
INTENSITY THERAPEUTICS, INC. Stock $ints

$ints Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023066740 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.139M	$362.5K	$619.9K
YoY Change	83.01%
% of Gross Profit
Research & Development	$1.352M	$859.2K	$891.1K
YoY Change	16.46%	-38.01%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.491M	$1.222M	$1.511M
YoY Change	39.68%	-36.69%
Operating Profit	-$2.491M	-$1.222M
YoY Change	40.88%	-36.69%
Interest Expense		$221.8K	$640.00
YoY Change		1382.58%
% of Operating Profit
Other Income/Expense, Net	$13.23K	$4.350K	$0.00
YoY Change	85.81%
Pretax Income	-$2.330M	-$3.701M	-$1.510M
YoY Change	31.26%
Income Tax
% Of Pretax Income
Net Earnings	-$2.330M	-$3.701M	-$1.510M
YoY Change	31.26%	91.97%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.17	-$1.05
Diluted Earnings Per Share	-$0.17	-$1.05	-$0.12
COMMON SHARES
Basic Shares Outstanding	13.68M shares	3.517M shares
Diluted Shares Outstanding	13.66M shares	3.517M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$15.69M	$135.8K	$1.312M
YoY Change	2153.01%
Cash & Equivalents	$6.694M	$135.8K	$1.312M
Short-Term Investments	$9.000M
Other Short-Term Assets	$14.37K	$159.5K	$76.16K
YoY Change	-85.61%
Inventory
Prepaid Expenses	$971.2K		$16.20K
Receivables
Other Receivables
Total Short-Term Assets	$16.63M	$18.06M	$1.450M
YoY Change	1850.56%
LONG-TERM ASSETS
Property, Plant & Equipment	$152.6K	$0.00	$139.1K
YoY Change	-17.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$28.44K	$167.7K	$167.7K
YoY Change	-83.05%
Total Long-Term Assets	$181.0K	$167.7K	$306.8K
YoY Change	-48.61%
TOTAL ASSETS
Total Short-Term Assets	$16.63M	$18.06M	$1.450M
Total Long-Term Assets	$181.0K	$167.7K	$306.8K
Total Assets	$16.82M	$18.23M	$1.757M
YoY Change	1295.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$358.4K	$1.582M	$603.2K
YoY Change	-54.99%
Accrued Expenses	$355.0K	$1.477M	$1.867M
YoY Change	-85.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$4.349M
YoY Change	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$724.0K	$3.058M	$6.818M
YoY Change	-86.55%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$180.9K	$36.00K	$36.00K
YoY Change	402.47%
Total Long-Term Liabilities	$180.9K	$36.00K	$36.00K
YoY Change	402.47%
TOTAL LIABILITIES
Total Short-Term Liabilities	$724.0K	$3.058M	$6.818M
Total Long-Term Liabilities	$180.9K	$36.00K	$36.00K
Total Liabilities	$904.9K	$3.094M	$6.854M
YoY Change	-83.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$47.34M	-$43.69M	-$38.65M
YoY Change
Common Stock	$1.371K	$1.310K	$341.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.91M	$15.13M	-$5.097M
YoY Change
Total Liabilities & Shareholders Equity	$16.82M	$18.23M	$1.757M
YoY Change	1295.41%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$2.330M	-$3.701M	-$1.510M
YoY Change	31.26%	91.97%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$5.119M	-$238.9K	-$1.635M
YoY Change	33.2%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$8.844M	$0.00
YoY Change
Cash From Investing Activities	-$8.844M	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	20.52M	-241.8K	2.250M
YoY Change
NET CHANGE
Cash From Operating Activities	-5.119M	-238.9K	-1.635M
Cash From Investing Activities	-8.844M	0.000
Cash From Financing Activities	20.52M	-241.8K	2.250M
Net Change In Cash	6.558M	-480.7K	615.3K
YoY Change	-270.66%
FREE CASH FLOW
Cash From Operating Activities	-$5.119M	-$238.9K	-$1.635M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1311877	usd
CY2023Q2	ints	Stock Subscriptions Receivable StockSubscriptionsReceivable	17765000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	159460	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	138459	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	18060225	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1450336	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139089	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167738	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167738	usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41109
	dei	Entity Registrant Name EntityRegistrantName	Intensity Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1488089
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 Enterprise Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 430
	dei	Entity Address City Or Town EntityAddressCityOrTown	Shelton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06484-4779
	dei	City Area Code CityAreaCode	(203)
	dei	Local Phone Number LocalPhoneNumber	221-7381
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	INTS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	13684377	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	135765	usd
CY2023Q2	us-gaap	Assets Assets	18227963	usd
CY2022Q4	us-gaap	Assets Assets	1757163	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1581812	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	603176	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1476633	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1723400	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	143221	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4348548	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3058445	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6818345	usd
CY2023Q2	ints	Related Party Deposit RelatedPartyDeposit	36000	usd
CY2022Q4	ints	Related Party Deposit RelatedPartyDeposit	36000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	3094445	usd
CY2022Q4	us-gaap	Liabilities Liabilities	6854345	usd
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1310	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	341	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	58822229	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23555160	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43690021	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38653008	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	15133518	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-15097182	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18227963	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1757163	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	859212	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1385966	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1632986	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3080466	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	362490	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	543830	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	842846	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1227853	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	1221702	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	1929796	usd
	us-gaap	Operating Expenses OperatingExpenses	2475832	usd
	us-gaap	Operating Expenses OperatingExpenses	4308319	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1221702	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1929796	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2475832	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4308319	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	171	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	213	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	487	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	856	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	221779	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	14959	usd
	us-gaap	Interest Expense InterestExpense	305161	usd
	us-gaap	Interest Expense InterestExpense	29754	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2261581	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2261581	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4349	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	16900	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5074	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	40528	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3700542	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1927642	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5037013	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4296689	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.05
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.26
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3516579	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3410103	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3463635	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3410103	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-15097182	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	624253	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	159262	usd
	ints	Warrants Issued To Underwriters In Connection With Public Offering WarrantsIssuedToUnderwritersInConnectionWithPublicOffering	1017146	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3031484	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16468516	usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	9999956	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6998580	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5037013	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	15133518	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-15962264	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	312126	usd
CY2023Q2	ints	Warrants Issued To Underwriters In Connection With Public Offering WarrantsIssuedToUnderwritersInConnectionWithPublicOffering	1017146	usd
CY2023Q2	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3031484	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16468516	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	9999956	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6998580	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-3700542	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	15133518	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-8684104	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500622	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4296689	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-12480171	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0397	pure
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-10776049	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	223520	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1927642	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-12480171	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5037013	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4296689	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	159262	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	139089	usd
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	88628	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	624253	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	500622	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2261581	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	21001	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-36121	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	978636	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	290834	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-246767	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	623496	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	145899	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	29754	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-143221	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-89756	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1139282	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2816990	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	242552	usd
	ints	Payout Of Fractional Shares On Reverse Split PayoutOfFractionalSharesOnReverseSplit	44	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	279338	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-36830	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1176112	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2816990	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1311877	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4539229	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	135765	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1722239	usd
CY2023Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3900000	shares
	ints	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable	17765000	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4736999	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	159262	usd
	ints	Warrants Issued To Underwriter In Connection With Stock Issuance WarrantsIssuedToUnderwriterInConnectionWithStockIssuance	1017146	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b>Note A — Nature of Business</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Intensity Therapeutics, Inc. (“the Company”) is a Connecticut based company that incorporated in Delaware in December 2012. The Company is a biotechnology company whose treatment approach addresses both the regional and systemic nature of a patient’s cancer. The Company’s DfuseRx<sup>SM</sup> technology platform has identified a lead drug, INT230-6.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">On April 27, 2023, the Company effected a two-for-one reverse stock split (“Reverse Stock Split”). All owners of record as of April 27, 2023 received one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common stock. All fractional shares created by the two-for-one exchange will be paid in cash. The conversion price of Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock reflect the Reverse Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock, all of which remain at $.0001. All holders of options and warrants had the exercise price doubled and the number of shares issuable upon exercise reduced by half. All current and prior period amounts related to shares, share prices and loss per share, presented in the Company’s financial statements and the accompanying notes have been restated for the Reverse Stock Split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As a result of its initial public offering (“IPO”), the Company began trading on the Nasdaq Capital Market under the symbol “INTS” on June 30, 2023 and on July 5, 2023 the Company received $17,765,000 in net cash proceeds after deducting the underwriter’s discounts, commissions, and legal expenses. These shares were formally issued on July 5, 2023 at the time that the net proceeds were transferred to the Company. The Company intends to use the net proceeds from the IPO to complete pre-clinical and clinical studies, submit regulatory filings to the United States Food & Drug Administration (“FDA”) and for general and corporate purposes.</span></p>
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company effected a two-for-one reverse stock split (“Reverse Stock Split”). All owners of record as of April 27, 2023 received one issued and outstanding share of the Company’s common stock in exchange for two outstanding shares of the Company’s common stock. All fractional shares created by the two-for-one exchange will be paid in cash. The conversion price of Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock reflect the Reverse Stock Split by doubling the original conversion price. The Reverse Stock Split has no impact on the par value per share of the Company’s common stock, Series A redeemable convertible preferred stock, Series B convertible preferred stock, and Series C convertible preferred stock, all of which remain at $.0001.
CY2023Q2	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	17765000	usd
CY2023Q2	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	43700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5000000	usd
CY2023Q2	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	136000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	20456000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>[2] Use of estimates:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The Company utilizes significant estimates and assumptions in valuing its stock-based awards. An additional significant estimate is that these financial statements are based on the assumption of the Company continuing as a going concern. See Note B with regard to the Company’s ability to continue as a going concern.</span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif"><b>[3] Concentration of credit risk:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The Company’s financial instruments that are exposed to concentrations of credit risk consist entirely of cash. These financial instruments are held at two U.S. financial institutions. The cash accounts are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to regulatory limits. During the six months ended June 30, 2023, the Company’s cash balances exceeded the FDIC insurance limit. The Company has not experienced any losses in such accounts. Although the Company believes that the financial institutions with whom the Company does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so beyond amounts guaranteed by the FDIC.</span></p>
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	422525	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	328527	usd
CY2023Q2	ints	Accrued Patient Costs Current AccruedPatientCostsCurrent	1050914	usd
CY2022Q4	ints	Accrued Patient Costs Current AccruedPatientCostsCurrent	1392604	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1705000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5359351	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: justify; color: #231F20"><span style="font-family: Times New Roman, Times, Serif"><b>[12] Reclassifications:</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in; color: #231F20"><span style="font-family: Times New Roman, Times, Serif">Certain prior year amounts have been reclassified to conform to current year presentation.</span></p>
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3194	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2269	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	54241	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	29359	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	16200	usd
CY2023Q2	ints	Advances To Vendors AdvancesToVendors	21488	usd
CY2022Q4	ints	Advances To Vendors AdvancesToVendors	14685	usd
CY2023Q2	us-gaap	Prepaid Taxes PrepaidTaxes	8785	usd
CY2022Q4	us-gaap	Prepaid Taxes PrepaidTaxes	15903	usd
CY2023Q2	ints	Receivable With Related Party ReceivableWithRelatedParty	69365	usd
CY2022Q4	ints	Receivable With Related Party ReceivableWithRelatedParty	46401	usd
CY2023Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	5581	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	15911	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	159460	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	138459	usd
CY2023Q2	ints	Deposit With Vendor Noncurrent DepositWithVendorNoncurrent	150000	usd
CY2022Q4	ints	Deposit With Vendor Noncurrent DepositWithVendorNoncurrent	150000	usd
CY2023Q2	ints	Deposit With Landlord Noncurrent DepositWithLandlordNoncurrent	17738	usd
CY2022Q4	ints	Deposit With Landlord Noncurrent DepositWithLandlordNoncurrent	17738	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167738	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	167738	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1476633	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1723400	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2261581	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2261581	usd
CY2022Q4	ints	Convertible Notes Payable Principal Current ConvertibleNotesPayablePrincipalCurrent	4250000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	98548	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4348548	usd
CY2023Q2	ints	Convertible Notes Payable Principal Current ConvertibleNotesPayablePrincipalCurrent	4492552	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	244447	usd
	us-gaap	Debt Instrument Convertible Number Of Equity Instruments DebtInstrumentConvertibleNumberOfEquityInstruments	1399716	pure
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	117700	usd
CY2023Q2	us-gaap	Share Price SharePrice	5
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	6
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0146	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q2	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	1800000	shares
CY2023Q2	us-gaap	Auction Market Preferred Securities Stock Series Shares Authorized AuctionMarketPreferredSecuritiesStockSeriesSharesAuthorized	4500000	shares
CY2021Q4	us-gaap	Employee Stock Ownership Plan Esop Shares In Esop EmployeeStockOwnershipPlanESOPSharesInESOP	2677500	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3000000	shares
	ints	Aggregate Percentage AggregatePercentage	0.035	pure
CY2023Q1	us-gaap	Auction Market Preferred Securities Stock Series Shares Authorized AuctionMarketPreferredSecuritiesStockSeriesSharesAuthorized	238700	shares
CY2021Q4	ints	Number Of Shares Underlying Options Outstanding At Beginning NumberOfSharesUnderlyingOptionsOutstandingAtBeginning	911250	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	8.57
CY2022Q1	ints	Number Of Shares Underlying Options Outstanding At Ending NumberOfSharesUnderlyingOptionsOutstandingAtEnding	911250	shares
CY2022Q1	ints	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Priceending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceendingBalance	8.57
CY2022Q2	ints	Number Of Shares Underlying Options Outstanding At Ending NumberOfSharesUnderlyingOptionsOutstandingAtEnding	911250	shares
CY2022Q2	ints	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Priceending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceendingBalance	8.57
CY2022Q1	ints	Number Of Shares Underlying Options Outstanding At Beginning NumberOfSharesUnderlyingOptionsOutstandingAtBeginning	1044250	shares
CY2022Q1	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	8.48
CY2023Q1	ints	Number Of Shares Underlying Options Outstanding At Ending NumberOfSharesUnderlyingOptionsOutstandingAtEnding	1044250	shares
CY2023Q1	ints	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Priceending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceendingBalance	8.48
CY2023Q2	ints	Number Of Shares Underlying Options Outstanding At Ending NumberOfSharesUnderlyingOptionsOutstandingAtEnding	1044250	shares
CY2023Q2	ints	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Priceending Balance SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceendingBalance	8.48
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	711875	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.63
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	593000	usd
CY2023Q2	ints	Unrecognized Compensation Cost Related UnrecognizedCompensationCostRelated	1543000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y8M12D
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	240000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	196000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	481000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	394000	usd
	ints	Expire Period Term ExpirePeriodTerm	P10Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y
CY2017Q1	ints	Square Feet SquareFeet	2534	usd
CY2017Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q1	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P3Y
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y3M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0392	pure
	ints	Operating Lease Payments Years OperatingLeasePaymentsYears	P5Y6M
CY2023Q2	us-gaap	Prepaid Rent PrepaidRent	2910	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	3275	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139089	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	143221	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	143221	usd
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2023Q2	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	36000	usd
CY2022Q4	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	36000	usd
	ints	Related To Agreement RelatedToAgreement	69400	usd
CY2022	ints	Related To Agreement RelatedToAgreement	46400	usd
	ints	Agreement Accrued AgreementAccrued	100000	usd
CY2022	ints	Agreement Accrued AgreementAccrued	95900	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	4000	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	65900	usd
CY2023Q2	ints	Related Party Tax Expense Due To Affiliates Current One RelatedPartyTaxExpenseDueToAffiliatesCurrentOne	-11000	usd
CY2022Q2	us-gaap	Related Party Tax Expense Due To Affiliates Current RelatedPartyTaxExpenseDueToAffiliatesCurrent	60000	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	23000	usd
	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	33700	usd
CY2023Q2	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	5700	usd
CY2022Q2	us-gaap	Related Party Tax Expense Due To Affiliates Deferred RelatedPartyTaxExpenseDueToAffiliatesDeferred	16900	usd
CY2023Q2	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	439400	usd
CY2023Q2	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	196600	usd
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1	pure
	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.03	pure
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	10000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	23000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	5000	usd
	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	10000	usd
CY2022Q4	ints	Stock Subscriptions Receivable StockSubscriptionsReceivable		usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.26
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.45
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3410103	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3410103	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3463635	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3516579	shares
	ints	Stock Issued During Period Value Preferred Stock For Anti Dilution Clauses StockIssuedDuringPeriodValuePreferredStockForAntiDilutionClauses		usd
CY2023Q2	ints	Stock Issued During Period Value Preferred Stock For Anti Dilution Clauses StockIssuedDuringPeriodValuePreferredStockForAntiDilutionClauses		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	ints	Payout Of Fractional Shares On Reverse Split PayoutOfFractionalSharesOnReverseSplit		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	ints	Proceeds From Subscription Receivable ProceedsFromSubscriptionReceivable		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued		usd
	ints	Warrants Issued To Underwriter In Connection With Stock Issuance WarrantsIssuedToUnderwriterInConnectionWithStockIssuance		usd
CY2023Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001567264

Files In Submission

Name	View Source	Status
0001213900-23-066740-index-headers.html	Edgar Link	pending
0001213900-23-066740-index.html	Edgar Link	pending
0001213900-23-066740.txt	Edgar Link	pending
0001213900-23-066740-xbrl.zip	Edgar Link	pending
f10q0623ex31-1_intensity.htm	Edgar Link	pending
f10q0623ex31-2_intensity.htm	Edgar Link	pending
f10q0623ex32-1_intensity.htm	Edgar Link	pending
f10q0623ex32-2_intensity.htm	Edgar Link	pending
f10q0623_intensity.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
ints-20230630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
ints-20230630_def.xml	Edgar Link	unprocessable
ints-20230630_lab.xml	Edgar Link	unprocessable
ints-20230630_pre.xml	Edgar Link	unprocessable
f10q0623_intensity_htm.xml	Edgar Link	completed
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
ints-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INTS
INTENSITY THERAPEUTICS, INC. Stock $ints

2023 Q3 Form 10-Q Financial Statement

#000121390023066740 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INTS INTENSITY THERAPEUTICS, INC. Stock $ints

2023 Q3 Form 10-Q Financial Statement

#000121390023066740 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INTS
INTENSITY THERAPEUTICS, INC. Stock $ints